Six-week, double-blind, placebo-controlled and long-term, open-label multicenter study of isoxicam in treatment of degenerative joint disease.
A new nonsteroidal anti-inflammatory drug, isoxicam (Maxicam), was studied in patients with degenerative joint disease of the knee or hip. During a six-week, double-blind, placebo-controlled phase involving 176 patients, isoxicam at a dosage of 200 mg once daily was significantly superior to placebo in parameters (knee) of night pain, pain on walking, starting pain, pain on motion, swelling, tenderness, maximal extension, maximal flexion, and limitation of range of motion, and in the parameter (hip) of pain on walking. In patients with knee involvement and those with hip involvement, isoxicam was superior to placebo in overall and global assessments of its efficacy by physicians and patients. When 165 patients continued in a long-term, open-label phase and received isoxicam, a further alleviation of symptoms was noted in those patients who had received isoxicam in the double-blind phase, and a marked and sustained improvement was seen in patients who had received placebo in the double-blind phase.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006621:Hip Joint; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy*; D007719:Knee Joint; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010894:Piroxicam / Q000031:analogs & derivatives*; D013843:Thiazines / Q000627:therapeutic use*
D013843:Thiazines; D010894:Piroxicam; C013580:isoxicam